What is the 13F Pro Quality Score for ACOG?

13F Pro ranks Alpha Cognition Inc. (ACOG) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ACOG's current score at https://13fpro.ai/company/ACOG (free sign-up required for the full ranking).

Where does 13F Pro source ACOG data?

All Alpha Cognition Inc. fundamentals and ownership data come directly from SEC EDGAR. Alpha Cognition Inc. files with the SEC under CIK 1655923. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ACOG in?

Alpha Cognition Inc. (ACOG) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ACOG research updated on 13F Pro?

ACOG's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Alpha Cognition Inc.(ACOG)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1655923 ACOG stock profile & AI dashboard →

13F Pro Quality Score

30.3/100

Rank #2,493 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ACOG Scores 30/100

exact factor attribution · 2026-09-11

ACOG's composite is driven by revenue growth, held back by free cash flow and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.6 pts

98th pct

Earnings growth

+0.5 pts

61th pct

Institutional flow

-1.3 pts

24th pct

Shareholder dilution

-2.1 pts

8th pct

Capital efficiency

-3.9 pts

12th pct

Earnings quality

-4.6 pts

4th pct

Profitability

-5.7 pts

12th pct

Scale

-6.1 pts

9th pct

Free cash flow

-6.2 pts

9th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in ACOG

Events flagged as statistical outliers against ACOG's own multi-year baseline — not fixed dollar thresholds.

Record insider buy2026-07-22
Largest insider buy on record for ACOG: Opaleye Management Inc. (TenPercentOwner) purchased $1,098,575
View source filing →

ACOG Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Alpha Cognition Inc. (ACOG), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACOG at 30.3/100 on a 32-signal composite quality model, placing it at rank #2,493 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Alpha Cognition Inc. reports quarterly revenue of $6.1M, net income of $-8.8M, free cash flow of $-7.0M. Top institutional holders of ACOG by reported 13-F value include Opaleye Management, Solas Capital Management, AWM Investment Company, based on the most recent SEC filings. ACOG trades on the Nasdaq exchange and files with the SEC under CIK 1655923. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACOG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alpha Cognition Inc. directly from SEC EDGAR. Alpha Cognition Inc.'s 13F Pro composite quality score has ranged between 29 and 30 since 2026, currently 30.3 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Alpha Cognition Inc.

Quirks, history, and lore behind ACOG — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company headquartered in Canada, listed on Nasdaq, focused on treating diseases of the central nervous system.
2
The Numbers
This is a micro-cap commercial-stage company with minimal revenue and a pipeline that lives and dies by a single approved product — classic high-risk, high-hope biotech math.
3
The History
The company gained U.S. commercial traction after receiving FDA approval for a drug targeting Alzheimer's disease — one of the most competitive and historically brutal spaces in all of drug development.
4
The Secret
Its approved drug works by inhibiting acetylcholinesterase — essentially the same mechanism as older Alzheimer's drugs — but is formulated as a once-daily extended-release treatment intended to improve on tolerability.
5
The Lore
The drug, Zunveyl, is a reformulation of a well-known generic compound, which means the science isn't new — the bet is entirely on better delivery winning over prescribers.
6
The Giveaway
Ticker ACOG, a tiny Canadian pharma punching into the U.S. Alzheimer's market with Zunveyl — a smarter spin on an old molecule, hoping doctors agree.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$6.1M

Net Income

Q2 2026

$-8.8M

Free Cash Flow

Q2 2026

$-7.0M

ROIC

Q2 2026

-58.6%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

$10.2MFY 2025

FY22 —FY23 —FY24 —FY25 $10.2M

Net Income

-39.8% YoY

$-20.7MFY 2025

FY22 —FY23 $-13.8MFY24 $-14.8MFY25 $-20.7M

Operating Income

-88.6% YoY

$-22.7MFY 2025

FY22 —FY23 $-9.9MFY24 $-12.0MFY25 $-22.7M

EPS (Diluted)

+42.2% YoY

$-1.18FY 2025

FY22 —FY23 $-3.84FY24 $-2.04FY25 $-1.18

Total Assets

+57.1% YoY

$79.7MFY 2025

FY22 —FY23 $2.5MFY24 $50.7MFY25 $79.7M

Op. Cash Flow

-162.8% YoY

$-20.4MFY 2025

FY22 —FY23 $-8.8MFY24 $-7.8MFY25 $-20.4M

Free Cash Flow

-165.7% YoY

$-20.7MFY 2025

FY22 —FY23 —FY24 $-7.8MFY25 $-20.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Revenue	$10.2M	—	—	—
Net Income	$-20.7M -39.8%	$-14.8M -7.4%	$-13.8M	—
Operating Income	$-22.7M -88.6%	$-12.0M -20.9%	$-9.9M	—
EPS (Diluted)	$-1.18 +42.2%	$-2.04 +46.9%	$-3.84	—
Total Assets	$79.7M +57.1%	$50.7M +1969.1%	$2.5M	—
Operating Cash Flow	$-20.4M -162.8%	$-7.8M +11.9%	$-8.8M	—
Free Cash Flow	$-20.7M -165.7%	$-7.8M	—	—

Get alerted when ACOG's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Alpha Cognition Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ACOG

Opaleye Management Inc.
$20.9M2,895,467 sh
Solas Capital Management, LLC
$13.9M1,924,617 sh
AWM Investment Company, Inc.
$12.1M1,672,168 sh
Cable Car Capital, LP
$10.0M1,382,339 sh
Ikarian Capital, LLC
$6.0M836,259 sh
SPHERA FUNDS MANAGEMENT LTD.
$3.9M545,816 sh
Alyeska Investment Group, L.P.
$2.6M365,000 sh
Aristides Capital LLC
$1.6M218,510 sh
BOOTHBAY FUND MANAGEMENT, LLC
$1.4M189,148 sh
CANTOR FITZGERALD, L. P.
$786.4K108,918 sh

Fund	Value	Shares
Opaleye Management Inc.	$20.9M	2,895,467
Solas Capital Management, LLC	$13.9M	1,924,617
AWM Investment Company, Inc.	$12.1M	1,672,168
Cable Car Capital, LP	$10.0M	1,382,339
Ikarian Capital, LLC	$6.0M	836,259
SPHERA FUNDS MANAGEMENT LTD.	$3.9M	545,816
Alyeska Investment Group, L.P.	$2.6M	365,000
Aristides Capital LLC	$1.6M	218,510
BOOTHBAY FUND MANAGEMENT, LLC	$1.4M	189,148
CANTOR FITZGERALD, L. P.	$786.4K	108,918

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ACOG on your watchlist

Track score changes the day Alpha Cognition Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ACOG a good stock to buy?

13F Pro's AI-powered analysis of Alpha Cognition Inc. (ACOG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACOG are available on the ACOG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ACOG is classified as a small company.

Which hedge funds own ACOG?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACOG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alpha Cognition Inc.'s investment landscape.